Literature DB >> 11119481

ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs.

M Yasuda1, Y Nakazato, H Yamashita, G Sekita, Y Kawano, Y Mineda, K Nakazato, T Tokano, M Sumiyoshi, Y Nakata.   

Abstract

Electrocardiographic changes were evaluated retrospectively in five patients without previous episodes of syncope or ventricular fibrillation who developed abnormal ST segment elevation mimicking the Brugada syndrome in leads V1-V3 after the administration of class Ic antiarrhythmic drugs. Pilsicainide (four patients) or flecainide (one patient) were administered orally for the treatment of symptomatic paroxysmal atrial fibrillation or premature atrial contractions. The QRS duration, QTc, and JT intervals on 12 lead surface ECG before administration of these drugs were all within normal range. After administration of the drugs, coved-type ST segment elevation in the right precordial leads was observed with mild QRS prolongation, but there were no apparent changes in JT intervals. No serious arrhythmias were observed during the follow up periods. Since ST segment elevation with mild QRS prolongation was observed with both pilsicainide and flecainide, strong sodium channel blocking effects in the depolarisation may have been the main factors responsible for the ECG changes. As the relation between ST segment elevation and the incidence of serious arrhythmias has not yet been sufficiently clarified, electrocardiographic changes should be closely monitored whenever class Ic drugs are given.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11119481      PMCID: PMC1729593          DOI: 10.1136/heart.85.1.e3

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  13 in total

Review 1.  Drug-induced J point elevation: a marker for genetic risk of sudden death or ECG curiosity?

Authors:  D M Roden; A A Wilde
Journal:  J Cardiovasc Electrophysiol       Date:  1999-02

2.  Dynamic changes of 12-lead electrocardiograms in a patient with Brugada syndrome.

Authors:  K Matsuo; W Shimizu; T Kurita; M Inagaki; N Aihara; S Kamakura
Journal:  J Cardiovasc Electrophysiol       Date:  1998-05

3.  Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease.

Authors:  H Kasanuki; S Ohnishi; M Ohtuka; N Matsuda; T Nirei; R Isogai; M Shoda; Y Toyoshima; S Hosoda
Journal:  Circulation       Date:  1997-05-06       Impact factor: 29.690

4.  Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts.

Authors:  R Brugada; J Brugada; C Antzelevitch; G E Kirsch; D Potenza; J A Towbin; P Brugada
Journal:  Circulation       Date:  2000-02-08       Impact factor: 29.690

5.  A study of the use of flecainide acetate in the long-term management of cardiac arrhythmias.

Authors:  M N Wiseman; J E Elstob; A J Camm; A W Nathan
Journal:  Pacing Clin Electrophysiol       Date:  1990-06       Impact factor: 1.976

6.  Genetic basis and molecular mechanism for idiopathic ventricular fibrillation.

Authors:  Q Chen; G E Kirsch; D Zhang; R Brugada; J Brugada; P Brugada; D Potenza; A Moya; M Borggrefe; G Breithardt; R Ortiz-Lopez; Z Wang; C Antzelevitch; R E O'Brien; E Schulze-Bahr; M T Keating; J A Towbin; Q Wang
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

7.  Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia.

Authors:  W Nakamura; K Segawa; H Ito; S Tanaka; N Yoshimoto
Journal:  J Cardiovasc Electrophysiol       Date:  1998-08

8.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

Authors:  D S Echt; P R Liebson; L B Mitchell; R W Peters; D Obias-Manno; A H Barker; D Arensberg; A Baker; L Friedman; H L Greene
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

9.  Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report.

Authors:  P Brugada; J Brugada
Journal:  J Am Coll Cardiol       Date:  1992-11-15       Impact factor: 24.094

10.  Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome.

Authors:  T Miyazaki; H Mitamura; S Miyoshi; K Soejima; Y Aizawa; S Ogawa
Journal:  J Am Coll Cardiol       Date:  1996-04       Impact factor: 24.094

View more
  4 in total

1.  Positive Brugada challenge test in V1 R-V3 R as a predictor of malignant prognosis in Brugada patients.

Authors:  Arash Hashemi; Shahab Shahrzad; Sorayya Shahrzad; Siamak Saber; Samira Taban; Amir Aslani; Zahra Emkanjoo
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-05-03       Impact factor: 1.468

Review 2.  Ventricular tachycardia in structurally normal hearts.

Authors:  T Scott Wall; Roger A Freedman
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

3.  Brugada pattern masquerading as ST-segment elevation myocardial infarction in flecainide toxicity.

Authors:  Lovely Chhabra; David H Spodick
Journal:  Indian Heart J       Date:  2012-06-22

4.  Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/- murine hearts modelling the Brugada syndrome.

Authors:  Kate S Stokoe; Richard Balasubramaniam; Catharine A Goddard; William H Colledge; Andrew A Grace; Christopher L-H Huang
Journal:  J Physiol       Date:  2007-02-15       Impact factor: 5.182

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.